Laboratory study of carumonam and clinical evaluation in respiratory tract infections

Seiichi Aonuma, Yoshihiro Honda, Reiko Ono, Noriko Otani, Kikuo Onuma, Akira Watanabe, Masako Sasaki, Kotaro Oizumi, Kiyoshi Konno

    Research output: Contribution to journalArticlepeer-review


    In vitro antimicrobial activity of carumonam (CRMN), a new monocyclic β-lactam antibiotic, was examined by the broth-dilution method using the MIC 2,000 system. The minimum inhibitory concentrations (WC's) of CRMN against 160 clinical isolates were compared with those of aztreonam (AZT) and cefoperazone (CPZ). Against Staphylococcus aureus, CRMN and AZT were shown to be less active than CPZ. But against all other isolates tested (Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Morganella morganii and Pseudomonas aeruginosa), CRMN and AZT were more active than CPZ. CRMN was administered by drip infusion for 1 h to one patient with diffuse panbronchiolitis at a dose of 1g, and its serum and sputum levels were assayed microbiologically. The peak serum level was 67.0 µg/ml and the peak sputum level was 1.52 µg/ml. CRMN was also administered to three patients with respiratory tract infections. Clinical response was excellent in one and good in two cases. No adverse reactions or abnormalitiesin laboratory findings were observed.

    Original languageEnglish
    Pages (from-to)268-275
    Number of pages8
    Publication statusPublished - 1987 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology


    Dive into the research topics of 'Laboratory study of carumonam and clinical evaluation in respiratory tract infections'. Together they form a unique fingerprint.

    Cite this